» Articles » PMID: 16316891

Preventive Effect of Nutritional Therapy Against Postoperative Recurrence of Crohn Disease, with Reference to Findings Determined by Intra-operative Enteroscopy

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2005 Dec 1
PMID 16316891
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to elucidate the predictive value of intra-operative enteroscopy (IOE) and the effect of enteral nutrition (EN) with regard to the postoperative recurrence of Crohn disease (CD).

Material And Methods: Forty patients requiring surgery for severe intestinal complications of CD were examined by IOE, and the severity of the remnant small intestine was determined. Patients were subclassified into either an EN group (>1,200 kcal/day) or a non-EN group (<1,200 kcal/day) according to the amount of daily EN intake after surgery. Contributions of IOE findings and EN to postoperative recurrence were analysed retrospectively.

Results: IOE identified intestinal lesions in 39 patients and active intestinal lesions in 24 patients. The cumulative rate of postoperative recurrence was significantly higher in patients with cobblestone appearance confirmed by IOE (p=0.006). However, other active intestinal lesions were not related to postoperative recurrence. EN reduced the cumulative rate of postoperative recurrence (p=0.017), especially in patients with penetrating type (p=0.005), in patients who did not have colitis (p=0.051) and in patients who did not have active intestinal lesions confirmed by IOE (p=0.02).

Conclusions: EN is a prophylactic that prevents the postoperative recurrence of small intestinal CD. Patients with the penetrating type of CD, and those who do not have active lesions in the small intestine according to IOE, are candidates for EN after surgery.

Citing Articles

Laparoscopic intracorporeal anastomosis open anastomosis for ileostomy reversal in Crohn's disease: A single center retrospective study.

Liu W, Xiong M, Chen G, Long Z, Xu C, Zhu L World J Gastrointest Surg. 2025; 17(1):98269.

PMID: 39872758 PMC: 11757179. DOI: 10.4240/wjgs.v17.i1.98269.


Review of exclusive enteral therapy in adult Crohn's disease.

Mitrev N, Huang H, Hannah B, Kariyawasam V BMJ Open Gastroenterol. 2021; 8(1).

PMID: 34580154 PMC: 8477235. DOI: 10.1136/bmjgast-2021-000745.


Medical therapies for postoperative Crohn's disease.

Shah R, Click B Therap Adv Gastroenterol. 2021; 14:1756284821993581.

PMID: 33643440 PMC: 7890708. DOI: 10.1177/1756284821993581.


Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.

Tamura S, Ishida N, Miyazu T, Onoue S, Tani S, Yamade M Sci Rep. 2020; 10(1):21353.

PMID: 33288852 PMC: 7721736. DOI: 10.1038/s41598-020-78603-9.


Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience.

Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V Intest Res. 2020; 18(2):184-191.

PMID: 32092799 PMC: 7206340. DOI: 10.5217/ir.2019.00094.